Mostrar el registro sencillo del ítem
| dc.contributor.author | Pons-Fuster, Eduardo | |
| dc.contributor.author | Riquelme-Pérez, Alejandro | |
| dc.contributor.author | Shumbar, Vyacheslav | |
| dc.contributor.author | González-Ponce, Celia-María | |
| dc.contributor.author | Fernández-Ávila, Juan-José | |
| dc.contributor.author | Ramon-Martínez, Andrés | |
| dc.contributor.author | Moreno-Belmonte, María-José | |
| dc.contributor.author | Cabañas-Perianes, Valentín | |
| dc.contributor.author | Pascual-Figal, Domingo-Andrés | |
| dc.contributor.author | Díaz-Carrasco, María-Sacramento | |
| dc.contributor.author | Caro-Martínez, César | |
| dc.date.accessioned | 2026-09-17T12:15:38Z | |
| dc.date.available | 2026-09-17T12:15:38Z | |
| dc.date.issued | 2026-06-12 | |
| dc.identifier.uri | https://sms.carm.es/ricsmur/handle/123456789/28138 | |
| dc.description.abstract | Background: Proteasome inhibitors (PIs) are integral in multiple myeloma (MM) treatment but carry a substantial risk of cardiovascular adverse events (CVAEs). The Heart Failure Association-International Cardio-Oncology Society (HFA-ICOS) risk score was designed to identify patients at risk of cardiotoxicity, but its performance in MM remains uncertain. Methods: We retrospectively evaluated 98 patients with MM or primary amyloidosis treated with PIs between 2019 and 2024 to externally validate and refine this score. Results: CVAEs occurred in 22 patients (22.5%), predominantly heart failure. The original HFA-ICOS model demonstrated modest predictive accuracy (AUC 0.66) and sensitivity (50%), with frequent risk overclassification. Carfilzomib exposure (HR 4.68, 95% CI 1.47-14.90; p = 0.009) and elevated NT-proBNP before cycle 2 (>300 pg/mL; HR 3.13, 95% CI 1.10-8.93; p = 0.033) independently predicted CVAEs. A dynamic model incorporating these parameters and adjusting the age threshold to ?65 years was associated with improved discrimination (AUC 0.72, p = 0.032), model fit (?AIC = -4), and CVAE-free survival stratification (p = 0.026), achieving 90.9% sensitivity. Conclusions: These findings indicate that the original HFA-ICOS score has limited prognostic value in PI-treated MM patients. Incorporating early NT-proBNP monitoring, carfilzomib exposure, and refined age categorization may improve risk prediction and support more personalized cardiovascular surveillance strategies in cardio-oncology. However, this refined dynamic model should be regarded as exploratory and requires validation in larger independent cohorts before it can be considered for clinical application. | |
| dc.language.iso | eng | |
| dc.publisher | MDPI | |
| dc.rights | Atribución/Reconocimiento 4.0 Internaciona | |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/deed.es | * |
| dc.title | Validation and Exploratory Refinement of the HFA-ICOS Score for Cardiovascular Risk in Proteasome Inhibitor-Treated Multiple Myeloma: Single-Center Retrospective Study | |
| dc.type | info:eu-repo/semantics/article | |
| dc.identifier.pmid | 42352458 | |
| dc.relation.publisherversion | https://www.mdpi.com/2072-6694/18/12/1924 | |
| dc.type.version | info:eu-repo/semantics/publishedVersion | |
| dc.identifier.doi | 10.3390/cancers18121924 | |
| dc.journal.title | CANCERS | |
| dc.identifier.essn | 2072-6694 |